Skip to main content
Fig. 7 | The Journal of Headache and Pain

Fig. 7

From: Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation

Fig. 7

Kaplan-Meier plots showing the cumulative incidence of participants achieving VLFEM among galcanezumab group, categorized by baseline migraine class: HFEM (blue line), CM (orange line), and overall (green line) over 6 months follow-up period

Abbreviation: CM: chronic migraine; HFEM: high-frequency episodic migraine; VLFEM: very low-frequency episodic migraine

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us